1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > NsGene A/S - Product Pipeline Review - 2014

NsGene A/S - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 24 pages

NsGene A/S - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘NsGene A/S - Product Pipeline Review - 2014’, provides an overview of the NsGene A/S’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NsGene A/S’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of NsGene A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NsGene A/S’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the NsGene A/S’s pipeline products

Reasons to buy

- Evaluate NsGene A/S’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NsGene A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NsGene A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NsGene A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NsGene A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of NsGene A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

NsGene A/S - Product Pipeline Review - 2014
Table of Contents
NsGene A/S Snapshot 4
NsGene A/S Overview 4
Key Information 4
Key Facts 4
NsGene A/S- Research and Development Overview 5
Key Therapeutic Areas 5
NsGene A/S- Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products- Monotherapy 8
Pipeline Products- Out-Licensed Products 9
Out-Licensed Products/Combination Treatment Modalities 10
NsGene A/S- Pipeline Products Glance 11
NsGene A/S- Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
NsGene A/S- Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
NsGene A/S- Drug Profiles 13
NsG-0202 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
NsG-0301 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
NsG-33 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
NsGene A/S- Pipeline Analysis 16
NsGene A/S- Pipeline Products by Target 16
NsGene A/S- Pipeline Products by Route of Administration 17
NsGene A/S- Pipeline Products by Molecule Type 18
NsGene A/S- Pipeline Products by Mechanism of Action 19
NsGene A/S- Recent Pipeline Updates 20
NsGene A/S- Dormant Projects 21
NsGene A/S- Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables

NsGene A/S, Key Information 4
NsGene A/S, Key Facts 4
NsGene A/S- Pipeline by Indication, 2014 6
NsGene A/S- Pipeline by Stage of Development, 2014 7
NsGene A/S- Monotherapy Products in Pipeline, 2014 8
NsGene A/S- Out-Licensed Products in Pipeline, 2014 9
NsGene A/S- Out-Licensed Products/ Combination Treatment Modalities, 2014 10
NsGene A/S- Phase I, 2014 11
NsGene A/S- Preclinical, 2014 12
NsGene A/S- Pipeline by Target, 2014 16
NsGene A/S- Pipeline by Route of Administration, 2014 17
NsGene A/S- Pipeline by Molecule Type, 2014 18
NsGene A/S- Pipeline Products by Mechanism of Action, 2014 19
NsGene A/S- Recent Pipeline Updates, 2014 20
NsGene A/S- Dormant Developmental Projects,2014 21

List of Figures

NsGene A/S - Pipeline by Top 10 Indication, 2014 6
NsGene A/S - Pipeline by Stage of Development, 2014 7
NsGene A/S - Monotherapy Products in Pipeline, 2014 8
NsGene A/S - Pipeline by Top 10 Target, 2014 16
NsGene A/S - Pipeline by Top 10 Route of Administration, 2014 17
NsGene A/S - Pipeline by Top 10 Molecule Type, 2014 18
NsGene A/S - Pipeline Products by Top 10 Mechanism of Action, 2014 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016’, ...

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H2 2016

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leucine Rich Repeat Serine/Threonine Protein Kinase ...

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.